USPTO Examiner GRABER JAMES J - Art Unit 1631

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19071148Viral Vectors For Treating Neurogenic Detrusor OveractivityMarch 2025October 2025Allow821YesNo
18616511Gene Therapy For Neurodegenerative DisordersMarch 2024March 2025Allow1110NoNo
18404087VECTOR-MEDIATED IMMUNE TOLERANCE IN THE EYEJanuary 2024June 2025Abandon1710NoNo
18534884Viral Vectors For Treating Neurogenic Detrusor OveractivityDecember 2023October 2024Abandon1111NoNo
18488346Gene Therapy For Neurodegenerative DisordersOctober 2023April 2025Abandon1810NoNo
18464908METHODS AND COMPOSITIONS FOR STEM CELL TRANSPLANTATIONSeptember 2023November 2025Abandon2611NoNo
18224131CELL-DERIVED PARTICLES PRESENTING HETEROLOGOUS CD24 AND USE THEREOF IN THERAPYJuly 2023October 2024Allow1520YesNo
18351930COMPOSITIONS AND METHODS OF TREATING HUNTINGTON'S DISEASEJuly 2023March 2025Abandon2001NoNo
18330020Protection of Beta Cells from Immune AttackJune 2023October 2025Allow2820NoNo
18142133COMPOSITIONS AND METHODS FOR TREATING SENSORINEURAL HEARING LOSS USING OTOFERLIN DUAL VECTOR SYSTEMSMay 2023October 2024Abandon1810YesNo
18309047METHODS FOR EXPANDING A POPULATION OF ALVEOLAR MACROPHAGES IN A LONG TERM CULTUREApril 2023December 2024Abandon2011NoNo
18140326TAIL-CONJUGATED RNASApril 2023May 2024Allow1221YesNo
18029158COMPOSITIONS AND METHODS FOR CD30 GENE MODIFICATIONMarch 2023March 2026Abandon3601NoNo
18114317CELL-DERIVED PARTICLES PRESENTING HETEROLOGOUS CD24 AND USE THEREOF IN THERAPYFebruary 2023August 2025Abandon2911NoNo
18110528T CELLS EXPRESSING CHEMOKINE RECEPTORS FOR TREATING CANCERFebruary 2023January 2026Abandon3531YesNo
18108869METHODS AND SYSTEMS FOR T CELL EXPANSIONFebruary 2023July 2025Allow2911YesNo
18167598Compositions and Methods of Treating Ocular DiseasesFebruary 2023January 2025Allow2411YesNo
18157494METHODS OF GENERATING POPULATIONS OF TUMOUR-INFILTRATING T CELLSJanuary 2023March 2026Abandon3821NoNo
18157598T CELL RECEPTOR (TCR) COMPOSITIONS AND METHODS FOR OPTIMIZING ANTIGEN REACTIVE T-CELLSJanuary 2023November 2025Allow3400YesNo
18016972DUAL CAR-T CELLSJanuary 2023January 2026Allow3610YesNo
18152464METHOD FOR ENHANCING PROLIFERATION CAPABILITY OF STEM CELLS USING ETHIONAMIDEJanuary 2023November 2024Allow2331YesNo
18004638IMMUNE CELLS WITH INCREASED GLYCOLYTIC FLUXJanuary 2023February 2026Abandon3701NoNo
18149396METHOD OF TREATING BREAST CANCER IN A SUBJECT BY INHIBITING NIP7 AND A PHARMACEUTICAL COMPOSITION COMPRISING A NIP7 INHIBITORJanuary 2023September 2025Allow3201YesNo
18149151Intrathecal Delivery of Recombinant Adeno-Associated Virus Encoding Methyl-CPG Binding Protein 2January 2023March 2025Allow2631YesNo
18068319CELLS EXPRESSING RECOMBINANT GROWTH FACTOR RECEPTORSDecember 2022June 2024Allow1810YesNo
18063589NOVEL ADENO-ASSOCIATED VIRUS CAPSID PROTEINSDecember 2022October 2024Abandon2220NoNo
17927663DIFFERENTIAL KNOCKOUT OF A HETEROZYGOUS ALLELE OF SAMD9LNovember 2022March 2026Abandon4001NoNo
18057960NON-HUMAN ANIMALS COMPRISING A HUMANIZED TTR LOCUS AND METHODS OF USENovember 2022February 2024Allow1511YesNo
17992168DEVICES AND METHODS FOR SIMULATING A FUNCTION OF LIVER TISSUENovember 2022September 2025Abandon3341NoNo
18054500Gene Therapy For Neurodegenerative DisordersNovember 2022January 2024Allow1420YesNo
17982753NUCLEOSIDE MODIFIED MRNA AND USES THEREOFNovember 2022March 2025Allow2822YesNo
18046363Gene Therapy For Neurodegenerative DisordersOctober 2022March 2024Allow1720YesYes
17958904T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOFOctober 2022June 2025Abandon3210NoNo
17882127CHIMERIC ANTIGEN RECEPTOR FOR SOLID CANCER AND T CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORAugust 2022January 2025Abandon2911NoNo
17882036CHIMERIC ANTIGEN RECEPTOR FOR SOLID CANCER AND T CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORAugust 2022January 2025Abandon2911NoNo
17882182CHIMERIC ANTIGEN RECEPTOR FOR SOLID CANCER AND T CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORAugust 2022April 2025Abandon3310NoNo
17814287DIMERIZATION SWITCHES AND USES THEREOFJuly 2022August 2024Abandon2511NoNo
17794939COMPOUNDS AND METHODS FOR TREATING OR REDUCING PRURITUSJuly 2022October 2025Allow3901YesNo
17793626PREVENTION OF PLATELET ACTIVATION AND CELL DIFFERENTIATION DURING THE PROCESSING OF BLOOD AND BLOOD-RELATED COMPOSITIONSJuly 2022October 2025Abandon3901NoNo
17866022VIRAL VECTORS FOR TREATING NEUROGENIC DETRUSOR OVERACTIVITYJuly 2022October 2025Allow3961YesYes
17789739INTRAPANCREATIC M2 POLARIZATION OF MACROPHAGES TO TREAT TYPE 1 DIABETESJune 2022October 2025Abandon4001NoNo
17851430CONUS-BASED TOXIN PEPTIDES, NUCLEIC ACIDS ENCODING SAME AND USES THEREOF IN MODULATING NMDA RECEPTORSJune 2022January 2026Allow4311YesNo
17747618COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLSMay 2022June 2024Abandon2511NoNo
17663344LMP-1 EXPRESSING CELLS AND METHODS OF USE THEREOFMay 2022December 2025Allow4311YesNo
17741744ELIMINATION OF PROLIFERATING CELLS FROM STEM CELL-DERIVED GRAFTSMay 2022February 2023Abandon900NoNo
17742209TARGETING GLIOBLASTOMA STEM CELLS THROUGH THE TLX-TET3 AXISMay 2022July 2025Allow3810NoNo
17774732COMBINED THERAPY FOR MUSCULAR DISEASESMay 2022February 2026Allow4511YesNo
17766648T CELLS MODIFIED TO EXPRESS MUTATED CXCR4 OR PARTIALLY DELETED AND USES THEREOFApril 2022December 2025Abandon4411NoNo
17766369COMPOSITION FOR REPROGRAMMING CELLS INTO PLASMACYTOID DENDRITIC CELLS OR INTERFERON TYPE I-PRODUCING CELLS, METHODS AND USES THEREOFApril 2022December 2025Allow4421YesNo
17765872METHODS OF ENGINEERING PLATELETS FOR TARGETING CIRCULATING TUMOR CELLSApril 2022January 2026Allow4501YesNo
17709208VISMODEGIB IN COMBINATION WITH A REPLICATION-DEFICIENT TYPE 5 ADENOVIRUS FOR EXPRESSION OF INTERFERON GAMMA FOR THE TREATMENT OF SKIN CANCERMarch 2022March 2025Abandon3510NoNo
17762529COMPOSITIONS AND METHODS TO TREAT METASTATIC GASTROINTESTINAL CANCERMarch 2022December 2025Allow4401YesNo
17642985NEW ONCOLYTIC NEWCASTLE DISEASE VIRUSES AND RECOMBINANT NDV STRAINSMarch 2022December 2025Abandon4501NoNo
17760724METHODS AND COMPOSITIONS FOR TREATING MYC-DRIVEN CANCERSMarch 2022July 2025Allow4110YesNo
17681167UNIVERSAL CAR-T CELL AND PREPARATION METHOD AND USE THEREOFFebruary 2022March 2025Allow3611YesNo
17665084ISOLATION OF FUSION-COMPETENT MYOBLASTS AND THERAPEUTIC APPLICATIONS THEREOF RELATED TO MUSCULAR DYSTROPHYFebruary 2022July 2025Abandon4120NoYes
17632686GENETICALLY ENGINEERED ONCOLYTIC VACCINIA VIRUSES AND METHODS OF USES THEREOFFebruary 2022September 2025Abandon4401NoNo
17590557RECOMBINANT ADENO-ASSOCIATED VIRUS VECTORS TO TARGET MEDULLARY THYROID CARCINOMAFebruary 2022December 2025Allow4720YesNo
17629627Aptamer-Based Multispecific Therapeutic AgentsJanuary 2022October 2025Abandon4501NoNo
17626360P21 Expressing Monocytes for Cancer Cell TherapyJanuary 2022September 2025Allow4511YesNo
17625483ONCOLYTIC NON-HUMAN ADENOVIRUSES AND USES THEREOFJanuary 2022February 2026Allow5011YesNo
17623978Use of LRP2 Agonists for Generating Myeloid-Derived Suppressor CellsDecember 2021July 2024Allow3011YesNo
17622224NUCLEIC ACID AGENTS MODULATING SLAMF6 ISOFORMSDecember 2021November 2025Allow4711YesNo
17620775METHODS FOR TRANSFORMATION OF FUNGAL SPORESDecember 2021November 2025Allow4711YesNo
17617336METHODS AND COMPOSITIONS FOR REDUCING GENE OR NUCLEIC ACID THERAPY-RELATED IMMUNE RESPONSESDecember 2021August 2025Abandon4401NoNo
17540289METHOD FOR PREVENTING OR TREATING METABOLIC DISORDERDecember 2021July 2023Allow1901YesNo
17610840INDUCING IMMUNE TOLERANCE BY rAAV VECTORSNovember 2021September 2025Abandon4601NoNo
17523627COMPOSITIONS AND METHODS FOR SELECTIVE GENE REGULATIONNovember 2021June 2025Allow4311YesNo
17516149TUMOR CELL VACCINESNovember 2021February 2024Abandon2711NoNo
17606890OPTIMIZED SUMF1 GENES AND EXPRESSION CASSETTES AND THEIR USEOctober 2021June 2025Allow4311NoNo
17604556GENE THERAPIES FOR STARGARDT DISEASE (ABCA4)October 2021July 2025Allow4411YesNo
17503132COMPLEMENTARY RNA LINKED BISPECIFIC T-CELL ENGAGING ANTIBODIESOctober 2021March 2024Allow2911YesNo
17602530NUCLEIC ACID MAZZOCCHIO AND METHODS OF MAKING AND USE THEREOFOctober 2021October 2025Allow4901YesNo
17447231VECTORIZED ANTIBODIES AND USES THEREOFSeptember 2021April 2024Abandon3111NoNo
17377972HIGH CONCENTRATION FORMULATIONSJuly 2021October 2025Abandon5121NoNo
17357704CYTOTOXIC MOLECULES RESPONSIVE TO INTRACELLULAR LIGANDS FOR SELECTIVE T CELL MEDIATED KILLINGJune 2021October 2025Allow5211YesNo
17342013SYNP162, A PROMOTER FOR THE EXPRESSION OF GENESJune 2021November 2022Allow1700YesNo
17327719CELL-DERIVED PARTICLES PRESENTING HETEROLOGOUS CD24 AND USE THEREOF IN THERAPYMay 2021August 2023Abandon2741NoNo
17325417Methods and Gene Therapy Constructs for Treating GM2 GangliosidosesMay 2021December 2022Allow1900YesNo
17288075PHARMACEUTICAL COMPOSITION COMPRISING ISOLATED MITOCHONDRIA FOR PREVENTING OR TREATING TENDINOPATHYApril 2021June 2025Allow5020NoNo
17223875SYNP159, A PROMOTER FOR THE EXPRESSION OF GENESApril 2021October 2022Allow1900YesNo
17222812GENETICALLY ENGINEERED HEMATOPOIETIC STEM CELLS AND USES THEREOFApril 2021September 2022Allow1721YesNo
17209035Method for Producing Culture Containing Megakaryocytes, and Method for Producing Platelets Using SameMarch 2021January 2024Allow3411YesNo
17274062CHIMERIC ANTIGEN RECEPTOR FOR SOLID CANCER AND T CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORMarch 2021January 2025Abandon4701NoNo
17186039CELL-DERIVED PARTICLES PRESENTING HETEROLOGOUS CD24 AND USE THEREOF IN THERAPYFebruary 2021December 2023Abandon3441YesYes
17183593METHODS OF MODULATING M2 MACROPHAGE POLARIZATION AND USE OF SAME IN THERAPYFebruary 2021June 2024Abandon4001NoNo
17268328CAR T-CELLS COMPRISING AN ANTI CD33, AN ANTI CLL1 AND AT LEAST ONE FURTHER CAR ANTI CD123 AND/OR FTL3February 2021November 2024Abandon4511NoNo
17141142BI-SPECIFIC TARGETED CHIMERIC ANTIGEN RECEPTOR T CELLSJanuary 2021May 2024Abandon4021NoNo
17256141Composition and Methods for Producing Insulin Producing Islet CellsDecember 2020January 2025Allow4921YesNo
17133187MODIFIED NATURAL KILLER CELLS AND NATURAL KILLER CELL LINES HAVING INCREASED CYTOTOXICITYDecember 2020October 2024Abandon4521YesNo
17107461ADENO-ASSOCIATED VIRUS VARIANTS AND METHODS OF USE THEREOFNovember 2020November 2023Abandon3610NoNo
16952801RECOMBINANT GLUT1 ADENO-ASSOCIATED VIRAL VECTOR CONSTRUCTS AND RELATED METHODS FOR RESTORING GLUT1 EXPRESSIONNovember 2020December 2025Abandon6071YesYes
17055525MANIPULATING ARID5B EXPRESSION IN IMMUNE CELLS TO PROMOTE METABOLISM, SURVIVAL, AND FUNCTIONNovember 2020June 2024Allow4311YesNo
17096502MODULATION OF LIVER GENESNovember 2020August 2023Abandon3301NoNo
17052818METHOD FOR TREATING AND MODELLING HEARING LOSSNovember 2020August 2025Allow5721YesNo
17084963NOVEL THERAPEUTICAL TOOLS AND METHODS FOR TREATING BLINDNESS BY TARGETING PHOTORECEPTORSOctober 2020November 2023Allow3611YesNo
16771781METHOD FOR PRODUCING ACTIVE GCMAFOctober 2020March 2025Allow5730YesNo
17050694ANTI-BCMA CAR-T-CELLS FOR PLASMA CELL DEPLETIONOctober 2020January 2024Abandon3901NoNo
17047761Cell-Containing Hydrogel Body and Method for Producing SameOctober 2020March 2025Allow5321YesNo
17047515Modification of Immune Cells to Increase ActivityOctober 2020July 2024Abandon4511NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner GRABER, JAMES J.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
4
Examiner Affirmed
3
(75.0%)
Examiner Reversed
1
(25.0%)
Reversal Percentile
37.7%
Lower than average

What This Means

With a 25.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
15
Allowed After Appeal Filing
2
(13.3%)
Not Allowed After Appeal Filing
13
(86.7%)
Filing Benefit Percentile
16.0%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 13.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner GRABER, JAMES J - Prosecution Strategy Guide

Executive Summary

Examiner GRABER, JAMES J works in Art Unit 1631 and has examined 112 patent applications in our dataset. With an allowance rate of 44.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 52 months.

Allowance Patterns

Examiner GRABER, JAMES J's allowance rate of 44.6% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by GRABER, JAMES J receive 2.63 office actions before reaching final disposition. This places the examiner in the 77% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by GRABER, JAMES J is 52 months. This places the examiner in the 3% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +57.4% benefit to allowance rate for applications examined by GRABER, JAMES J. This interview benefit is in the 96% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 13.5% of applications are subsequently allowed. This success rate is in the 9% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 12.5% of cases where such amendments are filed. This entry rate is in the 12% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 60.0% of appeals filed. This is in the 35% percentile among all examiners. Of these withdrawals, 66.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 84.4% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 4.0% of allowed cases (in the 77% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.